MCM
IBRX icon

MAI Capital Management’s ImmunityBio IBRX Stock Holding History

MAI Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$640K Buy
73,111
+268
+0.4% +$2.03K ﹤0.01% 1180
2026
Q1 		$559K Buy
72,843
+69,277
+1,943% +$474K ﹤0.01% 983
2025
Q4 		$7.06K Buy
3,566
+2,468
+225% +$5.59K ﹤0.01% 2985
2025
Q3 		$2.7K Buy
1,098
+750
+216% +$1.93K ﹤0.01% 3232
2025
Q2 		$919 Hold
348
– – ﹤0.01% 3641
2025
Q1 		$1.05K Hold
348
– – ﹤0.01% 3119
2024
Q4 		$891 Buy
+348
New +$1.45K ﹤0.01% 3214

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MAI Capital Management's IBRX Position: Q2 2026 in Review

MAI Capital Management increased its ImmunityBio (IBRX) stake by 0.37% in Q2 2026, buying an estimated $2.03K and bringing the position to 73,111 shares worth $640K. The position accounts for ﹤0.01% of the portfolio, ranked #1180.

MAI Capital Management first reported a position in IBRX in Q4 2024 and has held it in 7 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • MAI Capital Management held 73,111 shares of ImmunityBio worth $640K as of Q2 2026.
  • MAI Capital Management bought 268 ImmunityBio shares in Q2 2026, an estimated $2.03K.
  • ImmunityBio made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1180 holding.
  • MAI Capital Management first reported a position in ImmunityBio in Q4 2024 and has held it in 7 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.